بررسی پلی مرفیسم کدونهای 164 و 27 ژن گیرنده بتادو آدرنرژیک در زنان مبتلا به تخمدان پلی‌کیستیک

نوع مقاله: اصیل پژوهشی

نویسندگان

1 دانشیار مرکز تحقیقات بهداشت باروری ولیعصر (عج)، بیمارستان ولیعصر (عج)، مجتمع بیمارستانی امام خمینی، دانشگاه علوم پزشکی تهران، تهران، ایران

2 مربی گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی فسا، فسا، ایران

3 دانشجوی کارشناسی ارشد گروه بیولوژی و کلوپ محققان جوان، دانشکده علوم دارویی، دانشگاه آزاد اسلامی تهران، تهران، ایران

4 دانشجوی دکترای ژنتیک، گروه ژنتیک، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران

چکیده

مقدمه: سندرم تخمدان پلی‌کیستیک (PCOS) یک بیماری شایع و پیچیده در زنان است. اگرچه نقش عوامل ژنتیکی در PCOS به شدت مطرح است، ولی ژن‌هایی که در سبب شناسی یا اتیولوژی این سندرم درگیر است، تاکنون به طور کامل بررسی و گزارش نشده است. مطالعه حاضر با هدف بررسی ارتباط پلی مرفیسم یا چند شکلی دو کدون 164 و 27 ژن گیرنده بتادو آدرنرژیک در PCO انجام شد.
روش کار: این مطالعه مقطعی در سال 93-1392 بر روی 100 بیمار مبتلا به سندرم تخمدان پلی‌کیستیک در بیمارستان امام خمینی تهران انجام شد. نمونه خون به میزان 3 سی سی جهت ژنومیک DNA توسط کیت کیاژن استخراج و سپس پرایمر جهت PCR بر اساس بانک ژن تهیه شد. نمونه‌های DNA تأیید شده توسط شرکت Macrogen توالی شد و توالی‌های به دست آمده با نرم افزار Chromas (نسخه 4/2) مورد بررسی قرار گرفت. تجزیه و تحلیل داده‌ها با استفاده از روش بوت استراپ با استفاده از نرم‌افزار آماری SPSS (نسخه 18) انجام شد. میزان p کمتر از 05 /0 معنی دار در نظر گرفته شد.
یافته‌ها: تحلیل پلی مرفیسم کدون 164 نشان داد که در زنانPCO ، 4/44% پلی مرفیسم رخ داده بود که این تفاوت از نظر آماری معنی‌دار بود (002/0>p). کدون 27 تفاوت معنی‌داری را در پلی مرفیسم بین گروه‌های غیر PCOو PCO نشان نداد (606/0=p). هموزیگوت و هتروزیگوت هر دو کدون تفاوت معنی‌داری داشت، به ترتیب (004/0=p) و (0450/0=p)
نتیجه‌گیری: در بررسی پلی مرفیسم دو کدون 27 و 164 ژن گیرنده بتادو آدرنرژیک، کدون 164 با سندرم تخمدان پلی‌کیستیک همراهی دارد

کلیدواژه‌ها


عنوان مقاله [English]

Investigation of codons 164 and 27 of beta 2-adrenergic receptor gene polymorphism in women with the polycystic ovary syndrome

نویسندگان [English]

  • farideh Zangeneh 1
  • mohamad mahdi Naghizadeh 2
  • tayebeh Jafarian 3
  • saeedeh Nejad Fateh Moghadam 3
  • Arash Salmani 4
1 Associate Professor, Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 Instructor, Department of Community Medicine, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
3 M.Sc. student, Department of Biology, Young Researchers Club, School of Pharmaceutical Sciences, Tehran Islamic Azad University, Tehran, Iran
4 Ph.D. student of Genetics, Department of Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده [English]

Introduction: Polycystic ovary syndrome (PCOS) is a common and complex disease in women. Although the role of genetic factors in PCOS is strongly supported, the genes that are involved in the etiology of this syndrome have not yet been fully investigated. The aim of this study was the investigation of codons 164 and 27 of beta 2-adrenergic receptor gene polymorphism in women with PCOS.
Methods: This cross-sectional study was performed in 2014 on 100 women with PCOS in Imam Khomeini Hospital, Tehran, Iran. 3 ml blood samples were collected for extraction of genomic DNA by the Qiagen DNA extraction kit,  then gene bank based primers were prepared for PCR. Approved DNA samples were sequenced by Macrogen (row or sequence); resulting sequences were evaluated by the Chromas (ver. 2.4) application. The data were analyzed using the bootstrap method and SPSS software (ver.18). P < 0.05 was considered significant.
Findings: The analysis of polymorphism in codon 164 in PCO women showed 44.4% statistically significant polymorphism (P<0.002). Codon 27 did not show any significant polymorphism differences between PCO and non-PCO groups (P=0.606). Homozygous and heterozygous in both codons were significantly different (P=0.004 and P=0.0450, respectively).   
Conclusion: Inspection of beta2 adrenoceptor gene polymorphism in codons 164 and 27 showed that codon 164 is associated with PCO.

کلیدواژه‌ها [English]

  • Genetic polymorphism
  • Glu27Gl polymorphism
  • Polycystic ovary syndrome (PCOS)
  • Thr164Ile polymorphism
  • β2adrenoceptor
  1. Lara HE, Dissen GA, Leyton V, Paredes A, Fuenzalida H, Fiedler JL, et al. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000; 141(3):1059-72.
  2. Lara HE, McDonald JK, Ojeda SR. Involvement of nerve growth factor in female sexual development. Endocrinology 1990; 126(1):364-75.
  3. Adashi EY, Hsueh AJ. Stimulation of beta 2-adrenergic responsiveness by follicle-stimulating hormone in rat granulosa cells in vitro and in vivo. Endocrinology 1981; 108(6):2170-8.
  4. Lara HE, Ferruz JL, Luza S, Bustamante DA, Borges Y, Ojeda SR. Activation of ovarian sympathetic nerves in polycystic ovary syndrome. Endocrinology 1991; 133(6):2690-5.
  5. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftoline F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57(5):1320-9.
  6. Lobo RA, Kletzky OA, Campeau JD, diZerega GS. Elevated bioactive luteinizing hormone in women with polycystic ovary system. Fertil Steril 1981; 39(5):674-8.
  7. Norman RJ, Wu R, Stankiewiecz MT. 4: Polycystic ovary syndrome. Med J Aust 2004; 180(3):132-7.
  8. Kannel WB: The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5(2):27-37.
  9. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril2000; 73(1):150–6.
  10. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update2001; 7(6):522–5.
  11. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med2005; 352(12):1223–36.
  12. Jakubowski L. Genetic aspects of polycystic ovary syndrome. Endocrinol Pol 2005; 56(3):285-93.
  13. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006; 91(5):1660-6.
  14. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006; 29(1):278-85.
  15. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997; 12(12):2641-8.
  16. Polymorphism biology. Encyclopaedia Britaninica School and Library Subscribers. Available at: URL: http://www.britannica.com/science/polymorphism-biology; 2015.
  17. Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod Biol Endocrinol 2012; 10:36-43.
  18. Dasgupta S, Sirisha PV, Neelaveni K, Anuradha K, Sudhakar G, Reddy BM. Role of luteinizing hormone β-subunit gene variants among South Indian women with polycystic ovary syndrome. Gene 2012; 494(1):51-6.
  19. Kurabayashi T, Yahata T, Quan J, Tanaka K. Association of polymorphisms in the beta2 and beta3 adrenoceptor gene with polycystic ovary syndrome. J Reprod Med 2006; 51(5):389-93.
  20. Tellechea ML, Muzzio DO, Iglesias Molli AE, Belli SH, Graffigna MN, Levalle OA, et al. Association between β2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS. Clin Endocrinol 2013; 78(4):600-6.
  21. Daaka Y, Luttrel LM,lefkowists RJ.switching of the coupling of the beta2-adrenergic receptor to differentG protein by protein kinase A.Nature.1997;0390(6655):88-91.
  22. Rotterdom ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1):41-7.
  23. Luna SL, Neuman S, Aguilera J, Brown DI, Lara HE. In vivo β-adrenergic blockade by propranolol prevents isoproterenol-induced polycystic ovary in adult rats. Horm Metab Res 2012; 44(9):676-81.
  24. Marchetti B, Cioni M, Badr M, Folléa N, Pelletier G. Ovarian adrenergic nerves directly participate in the control of luteinizing hormone-releasing hormone and beta-adrenergic receptors during puberty: a biochemical and autoradiographic study. Endocrinology 1987; 121(1):219-26.
  25. Aguado LI, Petrovic Sl, Ojeda SR. Ovarian beta-adrenergic receptors during the onset of puberty: characterization, distribution, and coupling to steroidogenic responses. Endocrinology 1982; 110(4):1124-32.
  26. Merz1 C, Saller S, Kunz L, Xu J, Yeoman RR,Ting AY, et al. Expression of the beta-2 adrenergic receptor (ADRB-2) in human and monkey ovarian follicles: a marker of growing follicles? J Ovarian Res 2015; 8:8.
  27. Zafari Zangeneh F, Naghizadeh MM, Salman Yazd R, Abedinia N, Madani T. Effect of Ramadan fasting on activity of hypothalamus-pituitary-adrenal axis in polycystic ovary syndrome patients. Iran J Obstet Gynecol Infertil 2013; 16(57):7-16. (Persian).
  28. Zangeneh F, Naghizadeh MM, Abdollahi A, Bagheri M. Evaluation of neurohormones in sleep pattern of patients with polycystic ovary syndrome. Iran J Obstet Gynecol Infertil 2015; 17(130):10-20. (Persian).
  29. de Paiva AC, Marson FA, Ribeiro JD, Bertuzzo CS. Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors. Allergy Asthma Clin Immunol 2014; 10(1):8.
  30. Xu B, Arlehag L, Rantapää-Dahlquist SB, Lefvert AK. Beta2-adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Scand J Rheumatol 2004; 33(6):395-8.
  31. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005; 294(12):1526-33.
  32. Wallerstedt SM, Eriksson AL, Ohlsson C, Hedner T. Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic beta2 receptor in a Swedish hypertensive population. J Hum Hypertens 2005; 19(9):705-8.
  33. Gjesing AP, Andersen G, Burgdorf KS, Borch-Johnsen K, Jorgensen T, Hansen T, et al. Studies of the associations between functional beta2-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7808 white subjects. Diabetologia 2007; 50(3):563-8.
  34. Jalba MS, Rhoads GG, Demissie K. Association of codon 16 and codon 27 beta 2-adrenergic receptor gene polymorphisms with obesity: a meta-analysis. Obesity (Silver Spring) 2008; 16(9):2096-106.
  35. Wu HM, Bai H, Fan P, Liu R, Liu Y, Liu BW. Analysis of beta2-adrenergic receptor gene (beta2AR) Arg16Gly polymorphism in patients with endogenous hypertriglyceridemia in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008; 25(1):50-4.
  36. Lima JJ, Feng H, Duckworth L, Wang J, Sylvester JE, Kissoon N, et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism 2007; 56(6):757-65.
  37. Lin LH, Baracat MC, Maciel GA, Soares JM Jr, Baracat EC. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynaecol Obstet 2013; 120(2):115-8.
  38. Ramezani Tehrani F, Daneshpour M, Hashemi S, Zarkesh M, Azizi F. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. Iran J Reprod Med 2013; 11(3):185–94.
  39. Singhasena W, Pantasri T, Piromlertamorn W, Samchimchom S, Vutyavanich T. Follicle-stimulating hormone receptor gene polymorphism in chronic anovulatory women, with or without polycystic ovary syndrome: a cross-sectional study. Reprod Biol Endocrinol 2014, 12:86.
  40. Eriksena MB, Brusgaardd K, Andersena M, Tan Q, Altinok ML, Gaster M, et al. Association of polycystic ovary syndrome susceptibility single nucleotide polymorphism rs2479106 and PCOS in Caucasian patients with PCOS or hirsutism as referral diagnosis. Eur J Obstet Gynecol Reprod Biol 2012; 163(1):39-42.